EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ongoing Clinical Trials of Nonviral siRNA Therapeutics

Eshan A Narasipura iD, Rachel VanKeulen-Miller, Yutian Ma iD, Owen S Fenton iD

Bioconjugate Chemistry · 19.07.2023 · 34 (7) · 1177-1197

DOI: 10.1021/acs.bioconjchem.3c00205 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, online erschienen am 11.07.2023. Verfasst von Eshan A Narasipura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, N…. Hauptthemen laut MEDLINE: Nanoparticles. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 220 Literaturangaben. Gefördert von: UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Short interfering RNAs (siRNA) are a powerful class of genetic medicines whose clinical translation can be hindered by their suboptimal delivery properties in vivo. Here, we provide a clinically focused overview that summarizes ongoing siRNA clinical trials from the perspective of innovations in nonviral delivery strategies. More specifically, our review begins by highlighting the delivery barriers and physiochemical properties of siRNA that make it challenging to deliver it in vivo. We then provide commentary on specific delivery strategies, including sequence modification, siRNA ligand conjugation, and nanoparticle and exosomal packaging, each of which can be used to control the delivery of siRNA therapies in living systems. Last, we provide a summary table of ongoing siRNA clinical trials which also highlights the indication of use, target, and National Clinical Trial (NCT) number associated with each entry. In writing this review, our work aims to highlight the key challenges and strategies for effective nonviral siRNA delivery in vivo, while simultaneously summarizing information on ongoing clinical trials for siRNA therapy in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesHumansRNA, Small Interfering

Substanzen

RNA, Small Interfering

Autor:innen und Institutionen

  • Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
  • Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

ORCID-Profile: Eshan A Narasipura, Yutian Ma, Owen S Fenton

Förderung

  • UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

Zitieren

APA

Narasipura, E. A., VanKeulen-Miller, R., Ma, Y., & Fenton, O. S. (2023). Ongoing Clinical Trials of Nonviral siRNA Therapeutics. Bioconjugate Chemistry, 34(7), 1177-1197. https://doi.org/10.1021/acs.bioconjchem.3c00205

Vancouver

Narasipura EA, VanKeulen-Miller R, Ma Y, Fenton OS. Ongoing Clinical Trials of Nonviral siRNA Therapeutics. Bioconjugate Chemistry. 2023;34(7):1177-1197. doi:10.1021/acs.bioconjchem.3c00205

BibTeX
@article{Narasipura2023,
  author = {Narasipura, Eshan A and VanKeulen-Miller, Rachel and Ma, Yutian and Fenton, Owen S},
  title = {Ongoing Clinical Trials of Nonviral siRNA Therapeutics},
  journal = {Bioconjugate Chemistry},
  year = {2023},
  volume = {34},
  number = {7},
  pages = {1177--1197},
  doi = {10.1021/acs.bioconjchem.3c00205}
}
Kostenlos starten →